CLAIMS

1. A liquid pharmaceutical formulation comprising an effective amount of an antibody adalimumab and an amino acid.
2. The formulation as claimed in claim 1, wherein the concentration of antibody is between 1 mg / mL to 160 mg / mL preferably 1 mg / mL to 100 mg / mL.
3. The formulation as claimed in claim 2, wherein the concentration of antibody is 50 mg / mL.
4. The formulation as claimed in claim 1, wherein the pH of the formulation is between pH 4 and pH 8.
5. The formulation as claimed in claim 4, wherein the pH of the formulation is between pH 5.0 and pH 6.5, preferably at pH 5.2.
6. The formulation as claimed in claim 1 further comprising buffer system, wherein the buffer system is selected from histidine-buffers, citrate-buffers, succinate-buffers, acetate-buffers, phosphate-buffers, phosphate buffered saline, citrate and phosphate buffer, tromethamine buffers and suitable mixtures thereof.
7. The formulation as claimed in claim 6, wherein the buffer system is a succinate-buffer or acetate-buffer or histidine buffer or suitable mixture thereof.
8. The formulation as claimed in claim 6, wherein the buffer is in the concentration of 1mM to 100 mM, preferably 5 mM to 50 mM..
9. The formulation as claimed in claim 1, wherein the amino acid is selected from arginine, glycine, lysine, histidine, glutamic acid, aspartic acid, isoleucine, leucine, alanine, phenylalanine, tyrosine, tryptophane, methionine, serine, proline, cysteine / cystine and suitable combination thereof.
10. The formulation as claimed in claim 9, wherein the amino acid is arginine or glycine or histidine alone or in combination with other suitable amino acids.
11. The formulation as claimed in claim 1, comprising additional stabilizers selected from sugars and polyols, including their suitable combination.
12. The formulation as claimed in claim 11, wherein the sugar is selected from glucose, fructose, galactose, mannose, sorbose, ribose, deoxyribose, sucrose, trehalose, lactose, maltose, raffinose and suitable mixtures thereof preferably trehalose or raffinose.

13. The formulation as claimed in claim 11, wherein the polyol is selected from mannitol, sorbitol, dextran, glycerol, arabitol, propylene glycol, polyethylene glycol and suitable combinations thereof preferably mannitol or sorbitol.
14. The formulation as claimed in claim 9, wherein the amino acid is present in the concentration of 0.1% to 10%.
15. The formulation as claimed in claim 1 which further comprises suitable excipients selected from surfactants.
16. The formulation as claimed in claim 15, wherein the surfactant is selected from polyoxyethylensorbitan fatty acid esters (Tween), polyoxyethylene alkyl ethers, alkylphenylpolyoxyethylene ethers, polyoxyethylene-polyoxypropylene copolymer and sodium dodecyl sulphate (SDS).
17. The formulation as claimed in claim 16, wherein the surfactant is selected from polysorbate 20 or polysorbate 80.
18. The formulation as claimed in claim 15, wherein the surfactant is 0.001 % to 1 %.
19. A formulation as claimed in claim 1 comprising
    a) 1-160 mg / mL of adalimumab,
    b) 0.1-10% of stabilizer
    c) A buffer system with a pH of 4 to 8.
20. The formulation as claimed in claim 19, wherein the stabilizer is selected from sorbitol, raffinose, trehalose, arginine, lysine, glycine, mannitol, sucrose and combination thereof.
21. The formulation as claimed in claim 19,wherein the buffer is in the concentration of 1mM to 100 mM, preferably 5 mM to 50 mM.
22. The formulation as claimed in claim 19, wherein the antibody concentration is 50 mg / mL.
23. The formulation as claimed in claim 19, which further comprises a surfactant wherein the surfactant is polysorbate 80 or polysorbate 20.
24. A lyophilized formulation comprising the composition as claimed in claim 1-23.
25. The formulation of claim 24 wherein the lyophilized powder is reconstituted with water.